Literature DB >> 9014711

Cytokeratin 20 as an objective marker of urothelial dysplasia.

P Harnden1, I Eardley, A D Joyce, J Southgate.   

Abstract

OBJECTIVE: To investigate the dysregulation of cytokeratin 20 (CK20) expression in urothelial dysplasia and its potential as a diagnostic aid. PATIENTS AND METHODS: Twenty-two patients were selected on the basis that they had undergone one or more biopsies showing dysplasia before the development of a transitional cell carcinoma (TCC): 15 of these patients also had a prior history of TCC. The dysplasia was classified as mild in 12, moderate in 14 or severe dysplasia/carcinoma in situ in 10 patients, ensuring that a spectrum of morphological appearances was represented. Control biopsies were obtained from seven children undergoing bladder reconstructions and 23 patients with recurrent urinary tract infections, haematuria or functional bladder symptoms, but no history of TCC.
RESULTS: The expression of CK20 was restricted to superficial 'umbrella' cells and occasional intermediate cells in the control biopsies, even in the presence of severe inflammation. In 31 of the 36 cases of dysplasia complete loss of restriction was seen at least focally with positive expression in all layers of the urothelium.
CONCLUSION: The abnormal expression of CK20 is a reliable, positive marker of urothelial dysplasia in the urinary bladder. Immunostaining for CK20 is therefore a useful adjunct to morphology in the diagnosis of dysplasia, of particular value in the distinction from reactive states where diagnostic difficulties are greatest.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014711     DOI: 10.1046/j.1464-410x.1996.23511.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  22 in total

Review 1.  Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies.

Authors:  R Montironi; A Lopez-Beltran; R Mazzucchelli; D G Bostwick
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

Review 2.  Sleeping beauty: awakening urothelium from its slumber.

Authors:  Zarine R Balsara; Xue Li
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-25

Review 3.  The Urothelium: Life in a Liquid Environment.

Authors:  Marianela G Dalghi; Nicolas Montalbetti; Marcelo D Carattino; Gerard Apodaca
Journal:  Physiol Rev       Date:  2020-03-19       Impact factor: 37.312

Review 4.  When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.

Authors:  David J DeGraff; Justin M Cates; Joshua R Mauney; Peter E Clark; Robert J Matusik; Rosalyn M Adam
Journal:  Urol Oncol       Date:  2011-09-15       Impact factor: 3.498

5.  A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells.

Authors:  Angela Y Jia; Mireia Castillo-Martin; Josep Domingo-Domenech; Dennis M Bonal; Marta Sánchez-Carbayo; Jose M Silva; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

Review 6.  Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

7.  A study of cytokeratin 20 immunostaining in the urothelium of neuropathic bladder of patients with spinal cord injury.

Authors:  Subramanian Vaidyanathan; Ian W McDicken; Anna J Ikin; Paul Mansour; Bakul M Soni; Gurpreet Singh; Pradipkumar Sett
Journal:  BMC Urol       Date:  2002-07-29       Impact factor: 2.264

8.  Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells.

Authors:  Claire Lucy Varley; Jens Stahlschmidt; Barbara Smith; Michael Stower; Jennifer Southgate
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.

Authors:  Christine P Diggle; Sheena Cruickshank; Jonathon D Olsburgh; Stephanie Pellegrin; Barbara Smith; Rosamonde E Banks; Peter J Selby; Margaret A Knowles; Jennifer Southgate; Patricia Harnden
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.